Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the USBusiness Wire • 06/03/25
Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal CancerBusiness Wire • 05/30/25
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain StockZacks Investment Research • 05/19/25
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025Business Wire • 05/15/25
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development OfficerBusiness Wire • 05/12/25
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/29/25
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACRBusiness Wire • 04/28/25
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment InnovationBusiness Wire • 03/19/25
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL ProgramBusiness Wire • 03/11/25
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed PublicationsBusiness Wire • 02/26/25
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor ConferenceBusiness Wire • 02/25/25
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial ReportBusiness Wire • 02/25/25
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual MeetingBusiness Wire • 02/24/25
CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual MeetingBusiness Wire • 02/24/25